WHO Janssen Approved
[천지일보=이솜 기자] The World Health Organization (WHO) approved the emergency use of a novel coronavirus infection (Corona 19) vaccine developed by the US pharmaceutical company Johnson & Johnson (J&J) on the 12th (local time).
The WHO announced that it has added the J&J subsidiary Janssen’s Corona 19 vaccine to the urgent use list.
With this approval, the vaccine can be distributed through COVAX, an international vaccine partnership.
In addition to providing COVID-19 protection, the Janssen vaccine can be stored for 3 months at refrigerator temperatures rather than cryogenic temperatures. Therefore, it is suitable for use in countries or regions where freezers and cryogenic storage are not available. In addition, unlike other vaccines that require two vaccinations at a certain time, one vaccination can be effective.
WHO Secretary General Thewardros Adhanom Gobruyesus said, “As new vaccines become available, we need to ensure that the vaccines become part of the global COVID-19 solution.” Said.
WHO will convene an advisory group next week to develop official guidance on the use of the vaccine.
Cobax has reserved 500 million doses of vaccine, but Johnson & Johnson is experiencing production problems and has signed a contract to provide 200 million doses to the United States.
Johnson & Johnson is expected to help speed up the manufacturing process by forming a production alliance with the pharmaceutical giant Merck.
WHO Senior Advisor Bruce Aylward said at a video press briefing that day, “We hope to have access to that order by at least July.”
‘;
Copyright © Cheonji Ilbo-Unauthorized reproduction and redistribution of the press release of hope for a new era is prohibited.